Greenwich LifeSciences Set to Join Russell 2000 Index Again
June 26 2024 - 6:33AM
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a
clinical-stage biopharmaceutical company focused on its Phase III
clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an
immunotherapy to prevent breast cancer recurrences, today announced
that it is set to join the Russell 2000 and Russell 3000 Indexes at
the conclusion of the Russell indexes annual reconstitution,
effective after the US markets open on July 1, 2024, according to a
list of additions updated as of June 21, 2024.
CEO Snehal Patel commented, "The addition of our
company to the Russell 2000 Index may further increase our
institutional ownership as it did in 2021 and is a reflection of
the progress we have made in expanding FLAMINGO-01 into Europe and
into up to 150 clinical sites globally."
About FTSE Russell
FTSE Russell is a global index leader that
provides innovative benchmarking, analytics and data solutions for
investors worldwide. For over 30 years, leading asset owners, asset
managers, ETF providers and investment banks have chosen FTSE
Russell indexes to benchmark their investment performance and
create ETFs, structured products and index-based derivatives.
Approximately $10.5 trillion in assets are benchmarked against
Russell's US indexes. FTSE Russell primarily uses objective,
market-capitalization rankings, and style attributes to determine
membership for its Russell indexes. Membership in the small-cap
Russell 2000 Index, which remains in place for one year, is based
on membership in the broad-market Russell 3000 Index. For more
information on the Russell 2000 Index and the Russell indexes
reconstitution, visit the FTSE Russell website at:
https://www.ftserussell.com/resources/russell-reconstitution.
About FLAMINGO-01 and
GLSI-100
FLAMINGO-01 (NCT05232916) is a Phase III
clinical trial designed to evaluate the safety and efficacy of
GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who
had residual disease or high-risk pathologic complete response at
surgery and who have completed both neoadjuvant and postoperative
adjuvant trastuzumab based treatment. The trial is led by Baylor
College of Medicine and currently includes US clinical sites from
university-based hospitals and cooperative networks with plans to
expand into Europe and to open up to 150 sites globally. In the
double-blinded arms of the Phase III trial, approximately 500
HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up
to 250 patients of other HLA types will be treated with GLSI-100 in
a third arm. The trial has been designed to detect a hazard ratio
of 0.3 in invasive breast cancer-free survival, where 28
events will be required. An interim analysis for superiority and
futility will be conducted when at least half of those events, 14,
have occurred. This sample size provides 80% power if the annual
rate of events in placebo-treated subjects is 2.4% or greater.
For more information on FLAMINGO-01, please
visit the Company's website here and clinicaltrials.gov here.
Contact information and an interactive map of the majority of
participating clinical sites can be viewed under the "Contacts
and Locations" section. Please note that the interactive map is not
viewable on mobile screens. Related questions and participation
interest can be emailed
to: flamingo-01@greenwichlifesciences.com
About Breast Cancer and
HER2/neu Positivity
One in eight U.S. women will develop invasive
breast cancer over her lifetime, with approximately 282,000 new
breast cancer patients and 3.8 million breast cancer survivors in
2021. HER2 (human epidermal growth factor receptor 2) protein is a
cell surface receptor protein that is expressed in a variety of
common cancers, including in 75% of breast cancers at low (1+),
intermediate (2+), and high (3+ or over-expressor) levels.
About Greenwich LifeSciences,
Inc.
Greenwich LifeSciences is a clinical-stage
biopharmaceutical company focused on the development of GP2, an
immunotherapy to prevent breast cancer recurrences in patients who
have previously undergone surgery. GP2 is a 9 amino acid
transmembrane peptide of the HER2 protein, a cell surface receptor
protein that is expressed in a variety of common cancers, including
expression in 75% of breast cancers at low (1+), intermediate (2+),
and high (3+ or over-expressor) levels. Greenwich LifeSciences has
commenced a Phase III clinical trial, FLAMINGO-01. For more
information on Greenwich LifeSciences, please visit the Company's
website at www.greenwichlifesciences.com and follow the Company's
Twitter at https://twitter.com/GreenwichLS.
Forward-Looking Statement
Disclaimer
Statements in this press release contain
"forward-looking statements" that are subject to substantial risks
and uncertainties. All statements, other than statements of
historical fact, contained in this press release are
forward-looking statements. Forward-looking statements contained in
this press release may be identified by the use of words such as
"anticipate," "believe," "contemplate," "could," "estimate,"
"expect," "intend," "seek," "may," "might," "plan," "potential,"
"predict," "project," "target," "aim," "should," "will," "would,"
or the negative of these words or other similar expressions,
although not all forward-looking statements contain these words.
Forward-looking statements are based on Greenwich LifeSciences
Inc.'s current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict,
including statements regarding the intended use of net proceeds
from the public offering; consequently, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Further, certain forward-looking statements are based
on assumptions as to future events that may not prove to be
accurate. These and other risks and uncertainties are described
more fully in the section entitled "Risk Factors" in Greenwich
LifeSciences' Annual Report on Form 10-K for the year ended
December 31, 2022 and other periodic reports filed with the
Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and
Greenwich LifeSciences, Inc. undertakes no duty to update such
information except as required under applicable law.
Company ContactSnehal
PatelInvestor RelationsOffice: (832) 819-3232Email:
info@greenwichlifesciences.com
Investor & Public Relations Contact
for Greenwich LifeSciencesDave GentryRedChip Companies
Inc.Office: 1-800-RED CHIP (733 2447)Email: dave@redchip.com
Greenwich LifeSciences (NASDAQ:GLSI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greenwich LifeSciences (NASDAQ:GLSI)
Historical Stock Chart
From Jul 2023 to Jul 2024